Clinical Trial

TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma

Study acronym: TARGET-HCC
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are: * will the TheraBionic P1 device affect overall survival in advance HCC * the long term safety and tolerability of the TheraBionic P1 device * assessment of how the disease responded to the TheraBionic P1 device
Protocol Amendment History 2 changes
notable Primary completion pushed: 2027-08-31 -> 2028-08-31 2026-04-14
minor Completion pushed: 2027-08-31 -> 2028-08-31 2026-04-14
Trial Details
NCT Number NCT07118202
Lead Sponsor Barbara Ann Karmanos Cancer Institute
Collaborators: THERABIONIC INC.
Conditions Hepatocellular Carcinoma Recurrent
Enrollment 198 participants
Start Date 2025-10-20
Primary Completion 2028-08-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-13